JP5166441B2 - 癌治療用イミダゾリジノニルアミノピリミジン化合物 - Google Patents
癌治療用イミダゾリジノニルアミノピリミジン化合物 Download PDFInfo
- Publication number
- JP5166441B2 JP5166441B2 JP2009543061A JP2009543061A JP5166441B2 JP 5166441 B2 JP5166441 B2 JP 5166441B2 JP 2009543061 A JP2009543061 A JP 2009543061A JP 2009543061 A JP2009543061 A JP 2009543061A JP 5166441 B2 JP5166441 B2 JP 5166441B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- group
- mmol
- hydrogen
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 14
- 201000011510 cancer Diseases 0.000 title claims abstract description 11
- ZNTGGSMSFRDDIR-UHFFFAOYSA-N N1(CNCC1)NC1=NC=CC=N1 Chemical class N1(CNCC1)NC1=NC=CC=N1 ZNTGGSMSFRDDIR-UHFFFAOYSA-N 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 34
- 239000001257 hydrogen Substances 0.000 claims abstract description 31
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 4
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 85
- 125000005843 halogen group Chemical group 0.000 claims description 18
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims description 6
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 208000006359 hepatoblastoma Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 201000006958 oropharynx cancer Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 claims 1
- 108010056274 polo-like kinase 1 Proteins 0.000 abstract description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 5
- VLUNZXPZDFIDHY-UHFFFAOYSA-N 1-(2-aminopyrimidin-4-yl)imidazolidin-2-one Chemical class NC1=NC=CC(N2C(NCC2)=O)=N1 VLUNZXPZDFIDHY-UHFFFAOYSA-N 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 129
- 239000000243 solution Substances 0.000 description 73
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 239000000203 mixture Substances 0.000 description 57
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 44
- 238000002360 preparation method Methods 0.000 description 39
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 37
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- 239000007787 solid Substances 0.000 description 29
- 229920006395 saturated elastomer Polymers 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- 238000000034 method Methods 0.000 description 22
- 239000011780 sodium chloride Substances 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- 229910052938 sodium sulfate Inorganic materials 0.000 description 19
- 235000011152 sodium sulphate Nutrition 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 239000010410 layer Substances 0.000 description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- -1 pyridinyl compound Chemical class 0.000 description 12
- 239000007858 starting material Substances 0.000 description 11
- 239000012043 crude product Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 230000011278 mitosis Effects 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 239000004327 boric acid Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- NOICDPBEDNMHQK-UHFFFAOYSA-N 7-bromo-1-benzothiophene Chemical compound BrC1=CC=CC2=C1SC=C2 NOICDPBEDNMHQK-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- XVPCCIKIXUDQKP-UHFFFAOYSA-N 2-chloro-4-[7-(2-chloropyridin-4-yl)-1-benzothiophen-2-yl]pyrimidine Chemical compound C1=NC(Cl)=CC(C=2C=3SC(=CC=3C=CC=2)C=2N=C(Cl)N=CC=2)=C1 XVPCCIKIXUDQKP-UHFFFAOYSA-N 0.000 description 3
- QBCHAVSIELFPPP-UHFFFAOYSA-N 2-chloro-4-iodo-5-(methoxymethoxy)pyridine Chemical compound COCOC1=CN=C(Cl)C=C1I QBCHAVSIELFPPP-UHFFFAOYSA-N 0.000 description 3
- UEHRAKHRJFMBOY-UHFFFAOYSA-N 3-(methoxymethoxy)pyridine Chemical compound COCOC1=CC=CN=C1 UEHRAKHRJFMBOY-UHFFFAOYSA-N 0.000 description 3
- HRQMITJARWOZDT-UHFFFAOYSA-N 4-(1-benzothiophen-7-yl)-2-chloropyridine Chemical compound C1=NC(Cl)=CC(C=2C=3SC=CC=3C=CC=2)=C1 HRQMITJARWOZDT-UHFFFAOYSA-N 0.000 description 3
- CXHOJLOLUDOQIT-UHFFFAOYSA-N 6-chloro-4-iodopyridin-3-ol Chemical compound OC1=CN=C(Cl)C=C1I CXHOJLOLUDOQIT-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 238000006069 Suzuki reaction reaction Methods 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000012799 strong cation exchange Methods 0.000 description 3
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 3
- SRQUKKXMVKOMKN-UHFFFAOYSA-N (6-fluoro-4-iodopyridin-3-yl)methanol Chemical compound OCC1=CN=C(F)C=C1I SRQUKKXMVKOMKN-UHFFFAOYSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- IDNYTLARUCTDGK-UHFFFAOYSA-N 1-(pyrimidin-2-ylamino)imidazolidin-2-one Chemical class N1(C(NCC1)=O)NC1=NC=CC=N1 IDNYTLARUCTDGK-UHFFFAOYSA-N 0.000 description 2
- NCQDYBJTTFCQCS-UHFFFAOYSA-N 1-[2-[[4-(7-bromo-1-benzothiophen-2-yl)-5-fluoropyrimidin-2-yl]amino]ethyl]imidazolidin-2-one Chemical compound N1=C(C=2SC3=C(Br)C=CC=C3C=2)C(F)=CN=C1NCCN1CCNC1=O NCQDYBJTTFCQCS-UHFFFAOYSA-N 0.000 description 2
- JCRBJFGTHIEUJV-UHFFFAOYSA-N 1-[2-[[4-[7-(2-chloropyridin-4-yl)-1-benzothiophen-2-yl]pyrimidin-2-yl]amino]ethyl]imidazolidin-2-one Chemical compound C1=NC(Cl)=CC(C=2C=3SC(=CC=3C=CC=2)C=2N=C(NCCN3C(NCC3)=O)N=CC=2)=C1 JCRBJFGTHIEUJV-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- MJZSYWVNPVRPDY-UHFFFAOYSA-N 2-chloro-5-(methoxymethoxy)pyridine Chemical compound COCOC1=CC=C(Cl)N=C1 MJZSYWVNPVRPDY-UHFFFAOYSA-N 0.000 description 2
- XIHADZNCYUWASW-UHFFFAOYSA-N 2-fluoro-5-(fluoromethyl)-4-iodopyridine Chemical compound FCC1=CN=C(F)C=C1I XIHADZNCYUWASW-UHFFFAOYSA-N 0.000 description 2
- GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- IJZNIWPHSCQVJU-UHFFFAOYSA-N 4-[2-(2-chloro-5-fluoropyrimidin-4-yl)-1-benzothiophen-7-yl]pyridin-3-ol Chemical compound OC1=CN=CC=C1C1=CC=CC2=C1SC(C=1C(=CN=C(Cl)N=1)F)=C2 IJZNIWPHSCQVJU-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- WGXZDYPGLJYBJW-UHFFFAOYSA-N chloroform;propan-2-ol Chemical compound CC(C)O.ClC(Cl)Cl WGXZDYPGLJYBJW-UHFFFAOYSA-N 0.000 description 2
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- IONSZLINWCGRRI-UHFFFAOYSA-N n'-hydroxymethanimidamide Chemical compound NC=NO IONSZLINWCGRRI-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- FXGNEIOGSGKPFL-UHFFFAOYSA-N tert-butyl n-(6-fluoropyridin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=C(F)N=C1 FXGNEIOGSGKPFL-UHFFFAOYSA-N 0.000 description 2
- XNOOBYCBSHSKSM-UHFFFAOYSA-N tert-butyl n-[6-fluoro-4-[2-[2-[2-(2-oxoimidazolidin-1-yl)ethylamino]pyrimidin-4-yl]-1-benzothiophen-7-yl]pyridin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C(F)C=C1C1=CC=CC2=C1SC(C=1N=C(NCCN3C(NCC3)=O)N=CC=1)=C2 XNOOBYCBSHSKSM-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 description 1
- 0 *c(c(-c1c2[s]c(-c3nc(NCCN(CCN4)C4=O)ncc3Cl)cc2ccc1)c1)cnc1F Chemical compound *c(c(-c1c2[s]c(-c3nc(NCCN(CCN4)C4=O)ncc3Cl)cc2ccc1)c1)cnc1F 0.000 description 1
- JOZLNWHVAGSSLH-UHFFFAOYSA-N 1-[2-[[4-(7-bromo-1-benzothiophen-2-yl)-5-chloropyrimidin-2-yl]amino]ethyl]imidazolidin-2-one Chemical compound N1=C(C=2SC3=C(Br)C=CC=C3C=2)C(Cl)=CN=C1NCCN1CCNC1=O JOZLNWHVAGSSLH-UHFFFAOYSA-N 0.000 description 1
- WOVXJFVMRVWOLJ-UHFFFAOYSA-N 1-[2-[[4-[7-(3-amino-2-fluoropyridin-4-yl)-1-benzothiophen-2-yl]pyrimidin-2-yl]amino]ethyl]imidazolidin-2-one Chemical compound NC1=C(F)N=CC=C1C1=CC=CC2=C1SC(C=1N=C(NCCN3C(NCC3)=O)N=CC=1)=C2 WOVXJFVMRVWOLJ-UHFFFAOYSA-N 0.000 description 1
- JSRKJTDNAHLIOE-UHFFFAOYSA-N 1-[2-[[4-[7-(3-aminopyridin-4-yl)-1-benzothiophen-2-yl]-5-fluoropyrimidin-2-yl]amino]ethyl]imidazolidin-2-one Chemical compound NC1=CN=CC=C1C1=CC=CC2=C1SC(C=1C(=CN=C(NCCN3C(NCC3)=O)N=1)F)=C2 JSRKJTDNAHLIOE-UHFFFAOYSA-N 0.000 description 1
- LGQOWEOYCYQBAZ-UHFFFAOYSA-N 1-[2-[[4-[7-(5-amino-2-fluoropyridin-4-yl)-1-benzothiophen-2-yl]pyrimidin-2-yl]amino]ethyl]imidazolidin-2-one Chemical compound NC1=CN=C(F)C=C1C1=CC=CC2=C1SC(C=1N=C(NCCN3C(NCC3)=O)N=CC=1)=C2 LGQOWEOYCYQBAZ-UHFFFAOYSA-N 0.000 description 1
- VWCGJTFFADMLDZ-UHFFFAOYSA-N 1-[2-[[5-chloro-4-(7-pyridin-4-yl-1-benzothiophen-2-yl)pyrimidin-2-yl]amino]ethyl]imidazolidin-2-one Chemical compound N1=C(C=2SC3=C(C=4C=CN=CC=4)C=CC=C3C=2)C(Cl)=CN=C1NCCN1CCNC1=O VWCGJTFFADMLDZ-UHFFFAOYSA-N 0.000 description 1
- FEIFDKWXAXVGBG-UHFFFAOYSA-N 1-[2-[[5-chloro-4-[7-(5-chloro-2-fluoropyridin-4-yl)-1-benzothiophen-2-yl]pyrimidin-2-yl]amino]ethyl]imidazolidin-2-one Chemical compound C1=NC(F)=CC(C=2C=3SC(=CC=3C=CC=2)C=2C(=CN=C(NCCN3C(NCC3)=O)N=2)Cl)=C1Cl FEIFDKWXAXVGBG-UHFFFAOYSA-N 0.000 description 1
- BKAFWPUQWULECS-UHFFFAOYSA-N 1-[2-[[5-fluoro-4-[7-[2-fluoro-5-(hydroxymethyl)pyridin-4-yl]-1-benzothiophen-2-yl]pyrimidin-2-yl]amino]ethyl]imidazolidin-2-one Chemical compound OCC1=CN=C(F)C=C1C1=CC=CC2=C1SC(C=1C(=CN=C(NCCN3C(NCC3)=O)N=1)F)=C2 BKAFWPUQWULECS-UHFFFAOYSA-N 0.000 description 1
- VQXVCVTZSTYIMG-UHFFFAOYSA-N 2,2-dimethyl-n-pyridin-3-ylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=CN=C1 VQXVCVTZSTYIMG-UHFFFAOYSA-N 0.000 description 1
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 1
- WYDWNAIKLCKNGH-UHFFFAOYSA-N 2-chloro-4-[7-(3-ethoxypyridin-4-yl)-1-benzothiophen-2-yl]-5-fluoropyrimidine Chemical compound CCOC1=CN=CC=C1C1=CC=CC2=C1SC(C=1C(=CN=C(Cl)N=1)F)=C2 WYDWNAIKLCKNGH-UHFFFAOYSA-N 0.000 description 1
- QOXBRVMQZCDRLK-UHFFFAOYSA-N 2-chloro-5-fluoro-4-[7-(3-methoxypyridin-4-yl)-1-benzothiophen-2-yl]pyrimidine Chemical compound COC1=CN=CC=C1C1=CC=CC2=C1SC(C=1C(=CN=C(Cl)N=1)F)=C2 QOXBRVMQZCDRLK-UHFFFAOYSA-N 0.000 description 1
- RTDUMHJGLTYSTI-UHFFFAOYSA-N 2-fluoro-4-iodo-2-methyl-1h-pyridine Chemical compound CC1(F)NC=CC(I)=C1 RTDUMHJGLTYSTI-UHFFFAOYSA-N 0.000 description 1
- WAVYAFBQOXCGSZ-UHFFFAOYSA-N 2-fluoropyrimidine Chemical compound FC1=NC=CC=N1 WAVYAFBQOXCGSZ-UHFFFAOYSA-N 0.000 description 1
- WEVWMDXKENHVCZ-UHFFFAOYSA-N 3,4-dihydro-1h-pteridin-2-one Chemical class C1=CN=C2NC(=O)NCC2=N1 WEVWMDXKENHVCZ-UHFFFAOYSA-N 0.000 description 1
- IPBNQTRHMAXPRJ-UHFFFAOYSA-N 3-(2-aminoethyl)-1h-imidazol-2-one Chemical compound NCCN1C=CNC1=O IPBNQTRHMAXPRJ-UHFFFAOYSA-N 0.000 description 1
- HOPGXKHCKBRSQE-UHFFFAOYSA-N 4-(1-benzothiophen-7-yl)-2-fluoro-5-methylpyridine Chemical compound CC1=CN=C(F)C=C1C1=CC=CC2=C1SC=C2 HOPGXKHCKBRSQE-UHFFFAOYSA-N 0.000 description 1
- FUHRBQYAGQJEPL-UHFFFAOYSA-N 4-(1-benzothiophen-7-yl)-3-(methoxymethoxy)pyridine Chemical compound COCOC1=CN=CC=C1C1=CC=CC2=C1SC=C2 FUHRBQYAGQJEPL-UHFFFAOYSA-N 0.000 description 1
- HTCVGOVOAFNLFM-UHFFFAOYSA-N 4-[2-[2-[2-(2-oxoimidazolidin-1-yl)ethylamino]pyrimidin-4-yl]-1-benzothiophen-7-yl]pyridine-2-carbonitrile Chemical compound O=C1NCCN1CCNC1=NC=CC(C=2SC3=C(C=4C=C(N=CC=4)C#N)C=CC=C3C=2)=N1 HTCVGOVOAFNLFM-UHFFFAOYSA-N 0.000 description 1
- ZOSIXKLMVJHENK-UHFFFAOYSA-N 5-(bromomethyl)-2-fluoro-4-iodopyridine Chemical compound FC1=CC(I)=C(CBr)C=N1 ZOSIXKLMVJHENK-UHFFFAOYSA-N 0.000 description 1
- YTHMOBMZVVFNBE-UHFFFAOYSA-N 6-fluoropyridin-3-amine Chemical compound NC1=CC=C(F)N=C1 YTHMOBMZVVFNBE-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- QFIFNEQWCNKURX-UHFFFAOYSA-N BrCC=1C(=CC(=NC1)F)I.FC1=CC(=C(C=N1)CO)I Chemical compound BrCC=1C(=CC(=NC1)F)I.FC1=CC(=C(C=N1)CO)I QFIFNEQWCNKURX-UHFFFAOYSA-N 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- CBEZWUIKLKNNJX-UHFFFAOYSA-N FC1(CC=NC=C1C)I Chemical compound FC1(CC=NC=C1C)I CBEZWUIKLKNNJX-UHFFFAOYSA-N 0.000 description 1
- ISFJOIYOQXRVME-UHFFFAOYSA-N FC=1C(=NC=NC1)C1=CC2=C(S1)C(=CC=C2)C2=C(C=NC=C2)OCOC Chemical compound FC=1C(=NC=NC1)C1=CC2=C(S1)C(=CC=C2)C2=C(C=NC=C2)OCOC ISFJOIYOQXRVME-UHFFFAOYSA-N 0.000 description 1
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 1
- 230000037060 G2 phase arrest Effects 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- VEHBZMQYQCXPGH-UHFFFAOYSA-N S1C2=C(C=C1)C=CC=C2C2(NC=C(C=C2)C)F Chemical compound S1C2=C(C=C1)C=CC=C2C2(NC=C(C=C2)C)F VEHBZMQYQCXPGH-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 210000003793 centrosome Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- CWHRHCATIKFSND-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron Chemical compound [Fe].ClCCl.Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 CWHRHCATIKFSND-UHFFFAOYSA-L 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000008600 mitotic progression Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- UUMWMOYPOUKDRL-UHFFFAOYSA-N n-[4-[2-(2-chloro-5-fluoropyrimidin-4-yl)-1-benzothiophen-7-yl]pyridin-3-yl]-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CN=CC=C1C1=CC=CC2=C1SC(C=1C(=CN=C(Cl)N=1)F)=C2 UUMWMOYPOUKDRL-UHFFFAOYSA-N 0.000 description 1
- KSNXUMZOSGVVGQ-UHFFFAOYSA-N n-[4-[2-[5-fluoro-2-[2-(2-oxoimidazolidin-1-yl)ethylamino]pyrimidin-4-yl]-1-benzothiophen-7-yl]pyridin-3-yl]-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CN=CC=C1C1=CC=CC2=C1SC(C=1C(=CN=C(NCCN3C(NCC3)=O)N=1)F)=C2 KSNXUMZOSGVVGQ-UHFFFAOYSA-N 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
- VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910001494 silver tetrafluoroborate Inorganic materials 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- QPAZSNGSVRYMDE-UHFFFAOYSA-N tert-butyl n-(2-fluoropyridin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN=C1F QPAZSNGSVRYMDE-UHFFFAOYSA-N 0.000 description 1
- YRWKBNNRYUEFMI-UHFFFAOYSA-N tert-butyl n-[4-[2-(2-chloropyrimidin-4-yl)-1-benzothiophen-7-yl]-6-fluoropyridin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C(F)C=C1C1=CC=CC2=C1SC(C=1N=C(Cl)N=CC=1)=C2 YRWKBNNRYUEFMI-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87130206P | 2006-12-21 | 2006-12-21 | |
| US60/871,302 | 2006-12-21 | ||
| PCT/US2007/087044 WO2008076704A1 (en) | 2006-12-21 | 2007-12-11 | Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513552A JP2010513552A (ja) | 2010-04-30 |
| JP2010513552A5 JP2010513552A5 (enExample) | 2011-01-27 |
| JP5166441B2 true JP5166441B2 (ja) | 2013-03-21 |
Family
ID=39186811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543061A Expired - Fee Related JP5166441B2 (ja) | 2006-12-21 | 2007-12-11 | 癌治療用イミダゾリジノニルアミノピリミジン化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8101628B2 (enExample) |
| EP (1) | EP2125793B1 (enExample) |
| JP (1) | JP5166441B2 (enExample) |
| KR (1) | KR101088291B1 (enExample) |
| CN (1) | CN101563342B (enExample) |
| AT (1) | ATE479680T1 (enExample) |
| AU (1) | AU2007334039B2 (enExample) |
| BR (1) | BRPI0721045A2 (enExample) |
| CA (1) | CA2671738A1 (enExample) |
| DE (1) | DE602007008952D1 (enExample) |
| EA (1) | EA016177B1 (enExample) |
| ES (1) | ES2349169T3 (enExample) |
| MX (1) | MX2009006634A (enExample) |
| WO (1) | WO2008076704A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA016178B1 (ru) | 2006-12-21 | 2012-02-28 | Эли Лилли Энд Компани | Соединения имидазолидинониламинопиримидина |
| EP2155735A2 (en) | 2007-05-16 | 2010-02-24 | Eli Lilly And Company | Triazolyl aminopyrimidine compounds |
| TW200908981A (en) * | 2007-05-16 | 2009-03-01 | Lilly Co Eli | Triazolyl aminopyrimidine compounds |
| CN108853111B (zh) * | 2018-08-07 | 2020-06-05 | 浙江大学 | 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
| US6939877B2 (en) * | 2002-09-12 | 2005-09-06 | Wyeth | Antidepressant piperidine derivatives of heterocycle-fused benzodioxans |
| WO2004063192A1 (en) * | 2003-01-10 | 2004-07-29 | Pharmacopeia Drug Discovery, Inc. | Imidazolyl pyrimidine derivatives useful as il-8 receptor modulators |
| GB0308466D0 (en) | 2003-04-11 | 2003-05-21 | Novartis Ag | Organic compounds |
| WO2005012283A1 (en) * | 2003-07-31 | 2005-02-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted benzothiophene compounds and uses thereof |
| CN101115749B (zh) * | 2004-12-17 | 2011-06-22 | 安姆根有限公司 | 氨基嘧啶化合物和使用方法 |
| TW200800201A (en) * | 2005-11-18 | 2008-01-01 | Lilly Co Eli | Pyrimidinyl benzothiophene compounds |
| EP2001480A4 (en) * | 2006-03-31 | 2011-06-15 | Abbott Lab | Indazole CONNECTIONS |
| EA016178B1 (ru) | 2006-12-21 | 2012-02-28 | Эли Лилли Энд Компани | Соединения имидазолидинониламинопиримидина |
| EP2155735A2 (en) | 2007-05-16 | 2010-02-24 | Eli Lilly And Company | Triazolyl aminopyrimidine compounds |
| TW200908981A (en) | 2007-05-16 | 2009-03-01 | Lilly Co Eli | Triazolyl aminopyrimidine compounds |
-
2007
- 2007-12-11 AT AT07855058T patent/ATE479680T1/de not_active IP Right Cessation
- 2007-12-11 BR BRPI0721045-0A patent/BRPI0721045A2/pt not_active IP Right Cessation
- 2007-12-11 CN CN2007800472640A patent/CN101563342B/zh not_active Expired - Fee Related
- 2007-12-11 EP EP07855058A patent/EP2125793B1/en not_active Not-in-force
- 2007-12-11 US US12/516,514 patent/US8101628B2/en not_active Expired - Fee Related
- 2007-12-11 JP JP2009543061A patent/JP5166441B2/ja not_active Expired - Fee Related
- 2007-12-11 WO PCT/US2007/087044 patent/WO2008076704A1/en not_active Ceased
- 2007-12-11 CA CA002671738A patent/CA2671738A1/en not_active Abandoned
- 2007-12-11 MX MX2009006634A patent/MX2009006634A/es active IP Right Grant
- 2007-12-11 KR KR1020097012835A patent/KR101088291B1/ko not_active Expired - Fee Related
- 2007-12-11 ES ES07855058T patent/ES2349169T3/es active Active
- 2007-12-11 DE DE602007008952T patent/DE602007008952D1/de active Active
- 2007-12-11 AU AU2007334039A patent/AU2007334039B2/en not_active Ceased
- 2007-12-11 EA EA200970615A patent/EA016177B1/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN101563342A (zh) | 2009-10-21 |
| CN101563342B (zh) | 2012-09-05 |
| US8101628B2 (en) | 2012-01-24 |
| US20100076001A1 (en) | 2010-03-25 |
| ATE479680T1 (de) | 2010-09-15 |
| ES2349169T3 (es) | 2010-12-28 |
| EA016177B1 (ru) | 2012-02-28 |
| EA200970615A1 (ru) | 2009-10-30 |
| KR101088291B1 (ko) | 2011-11-30 |
| AU2007334039A1 (en) | 2008-06-26 |
| WO2008076704A1 (en) | 2008-06-26 |
| AU2007334039B2 (en) | 2012-02-16 |
| DE602007008952D1 (de) | 2010-10-14 |
| BRPI0721045A2 (pt) | 2014-07-29 |
| JP2010513552A (ja) | 2010-04-30 |
| EP2125793B1 (en) | 2010-09-01 |
| MX2009006634A (es) | 2009-06-30 |
| EP2125793A1 (en) | 2009-12-02 |
| CA2671738A1 (en) | 2008-06-26 |
| KR20090086114A (ko) | 2009-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5248600B2 (ja) | トリアゾリルアミノピリミジン化合物 | |
| US20100130496A1 (en) | Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase | |
| JP5166441B2 (ja) | 癌治療用イミダゾリジノニルアミノピリミジン化合物 | |
| KR101080594B1 (ko) | 암의 치료를 위한 이미다졸리디노닐 아미노피리미딘 화합물 | |
| JP5204838B2 (ja) | トリアゾリルアミノピリミジン化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101125 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101125 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20121211 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121220 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151228 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |